Prostate Cancer Diagnosis via STEAP-1 Antibody CTC Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for prostate cancer diagnosis, particularly for detecting circulating tumor cells (CTCs), lack reliability in distinguishing prostate cancer progression and are invasive, with PSA screening showing limited mortality reduction and causing unnecessary side effects.
Innovation Solution
A method involving contacting cancer cells from a blood sample with antibodies specific to prostate-specific markers like STEAP-1, followed by determining the expression levels and calculating a grade score (H score) to diagnose and stage prostate cancer, using techniques such as immunofluorescent microscopy or flow cytometry.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PSA screening is used to detect prostate cancer, then early detection is improved, but mortality reduction is limited and unnecessary side effects occur
Solution Approach 1:
The patent changes the detection parameter from general PSA antigen levels to specific CTC characteristics (epithelial markers, prostate-specific markers, viability). This parameter transformation enables more reliable cancer detection while reducing false positives that lead to unnecessary side effects.
Solution Approach 2:
The patent applies local quality by specifically targeting circulating tumor cells with dual-marker expression (epithelial + prostate-specific) rather than general PSA screening. This localized approach improves detection accuracy for actual cancer cases while avoiding unnecessary screening of benign conditions.
2Measurement precision
If biopsy is used for definitive diagnosis, then diagnostic accuracy is improved, but invasiveness increases
Solution Approach 1:
The patent replaces the mechanical invasive biopsy procedure with an in vitro immunophenotyping method using flow cytometry or microscopy. This substitution maintains high diagnostic accuracy by detecting specific cell surface markers while completely avoiding the invasiveness of tissue sampling.
Solution Approach 2:
The patent uses circulating tumor cells in blood as an intermediary to diagnose prostate cancer without directly sampling the prostate tissue. These CTCs serve as a non-invasive proxy that retains the diagnostic information needed for accurate cancer detection and staging.
3Productivity
If current CTC detection methods are used, then cell detection is achieved, but ability to distinguish prostate cancer progression is insufficient
Solution Approach 1:
The patent adds another dimension to CTC detection by implementing a dual-marker screening system (epithelial markers plus prostate-specific markers) instead of single-marker methods. This dimensional expansion enables not only CTC detection but also characterization of prostate cancer progression and origin.
Solution Approach 2:
The patent segments the CTC detection process into distinct analytical components: epithelial marker detection, prostate-specific marker detection, viability assessment, and quantitative analysis. This segmentation allows comprehensive evaluation of CTCs to determine prostate cancer progression while maintaining detection efficiency.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach provides a non-invasive, reliable method for diagnosing and staging prostate cancer, predicting therapy efficacy, and monitoring treatment response by accurately identifying and quantifying CTCs expressing prostate-specific markers.
Implementation Method 1
contacting cancer cells of epithelial origin with an antibody that specifically binds to a prostate-specific marker
Implementation Method 2
determining whether any of the cancer cells express the prostate-specific marker using techniques such as immunofluorescent microscopy or flow cytometry
Implementation Method 3
determining whether any of the cancer cells express the prostate-specific marker using techniques such as immunofluorescent microscopy or flow cytometry
Data Source
Figure 1~2B
Figure 2C~2D
Figure 3A~3B
AI summary
The invention provides methods for diagnosing prostate cancer. The invention also provides novel anti-STEAP-1 antibodies and uses thereof.